Abstract 1751P
Background
Myxoid liposarcoma (MLPS) constitutes around 15% of all liposarcoma. They are characterized by a specific translocation, the t(12;16), leading to the fusion of FUS to DDIT3, which confers specific molecular features. In this study, we assessed the clinical and survival data of MLPS pts (patients) with evaluation of the impact of various clinical and tumor features on survival outcomes.
Methods
This retrospective study included MLPS pts treated at Gustave Roussy between January 1990 and March 2024. All clinical features were gathered as well as survival data and management details. In addition, we performed univariate (UVA) and multivariate analyses (MVA) to evaluate the impact of various factors on survival (age, gender, adjuvant chemotherapy (CT) and radiation therapy (RT), primary site, and tumor grade (TG)).
Results
336 pts were included (median age of 43 yrs and 60.4% were men). They occurred in the lower arms (75.3%, 253 pts, most in the hip (73.1%)), followed by the trunk (9.8%, 33 pts). TG 1 tumor was in 172 pts (64.7%), TG 2 in 85 (31.9%), and TG 3 in 9 (3.4%). 311 pts had surgery (93.9%) of whom 165 had adjuvant RT (53.1%) while 78 received peri-operative CT (25.1%). Out of 317 pts, 85 had at least one local relapse (LR) (26.8%) with a median time to LR of 24.3 mo. At 6 mo, the LR-free survival (LR-FS) was 96% while the 1- and 5-year LRFS reached 92.2% and 75.8%. 95 had at least one metastatic relapse (MR) (30.3%) with a median time of 38.3 mo. [25.9;45.7]. At 6 mo., the MRFS was 98% while the 1- and 5-year reached 94.8% and 70.6%. The median OS was not reached (NR) [249; NR]. At 6 mo., the OS was 98.8% while the 1- and 5-year were 97.7% and 89.3%. In the UVA, adjuvant RT (p<0.001) and CT (p=0.008) had an impact on LR while in the MVA, adjuvant RT (p<0.001) and age (p=0.03) were significant. Male gender (p=0.01) and high TG (p=0.02) had a higher risk of MR as well as shorter survival (male gender (p=0.04) and TG (p=0.004)).
Conclusions
In one of the largest retrospective cohorts, 336 MLPS pts were commonly diagnosed with a tumor in the lower arms with a localized setting. It is characterized by a high risk of both local (26.8%) and distant relapse (30.3%) but with prolonged survival. Male gender and a higher tumor grade were associated with an increased risk of distant relapse and shorter survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1740P - Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial
Presenter: Yuhong Zhou
Session: Poster session 06
1741P - Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt
Presenter: Paolo G. Casali
Session: Poster session 06
1742P - Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study
Presenter: Pau Mascaró Baselga
Session: Poster session 06
1743P - A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
Presenter: Zhiguo Luo
Session: Poster session 06
1745P - How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center
Presenter: Sebastian Diaz
Session: Poster session 06
1746P - Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project
Presenter: Kenji Tsuchihashi
Session: Poster session 06
1747P - Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study
Presenter: Evelyne Roets
Session: Poster session 06
1748P - A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
Presenter: Xi Guo
Session: Poster session 06
1749P - Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified?
Presenter: Tania Moussa
Session: Poster session 06
1750P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Gale Rizzae Mercado Alcala
Session: Poster session 06